Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Drennan S, Chiodin G, D'Avola A, Tracy I, Johnson PW, Trentin L, Steele AJ, Packham G, Stevenson FK, Forconi F.

Clin Cancer Res. 2019 Apr 15;25(8):2503-2512. doi: 10.1158/1078-0432.CCR-18-1286. Epub 2018 Oct 29.

PMID:
30373751
2.

CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

Lezina L, Spriggs RV, Beck D, Jones C, Dudek KM, Bzura A, Jones GDD, Packham G, Willis AE, Wagner SD.

Blood Adv. 2018 Aug 14;2(15):1869-1881. doi: 10.1182/bloodadvances.2017015560.

3.

Metabolic targets of watercress and PEITC in MCF-7 and MCF-10A cells explain differential sensitisation responses to ionising radiation.

Giallourou NS, Rowland IR, Rothwell SD, Packham G, Commane DM, Swann JR.

Eur J Nutr. 2018 Jul 31. doi: 10.1007/s00394-018-1789-8. [Epub ahead of print]

4.

Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer.

Whitton B, Okamoto H, Packham G, Crabb SJ.

Cancer Med. 2018 Aug;7(8):3800-3811. doi: 10.1002/cam4.1594. Epub 2018 Jun 21. Review.

5.

Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity.

Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, Amador LA, Li L, Amin AD, Pongtornpipat P, Zerio CJ, Ambrose AJ, Paine-Murrieta G, Greninger P, Vega F, Benes CH, Packham G, Rodríguez AD, Chapman E, Schatz JH.

Clin Cancer Res. 2018 Sep 1;24(17):4256-4270. doi: 10.1158/1078-0432.CCR-17-3645. Epub 2018 May 29.

PMID:
29844128
6.

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.

Regufe da Mota S, Bailey S, Strivens RA, Hayden AL, Douglas LR, Duriez PJ, Borrello MT, Benelkebir H, Ganesan A, Packham G, Crabb SJ.

Cancer Cell Int. 2018 May 9;18:71. doi: 10.1186/s12935-018-0568-1. eCollection 2018.

7.

Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.

Papadakis ES, Reeves T, Robson NH, Maishman T, Packham G, Cutress RI.

Br J Cancer. 2018 Apr;118(8):1154. doi: 10.1038/s41416-018-0032-y. Epub 2018 Mar 15. No abstract available.

8.

Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk.

Del Vecchio F, Lee GH, Hawezi J, Bhome R, Pugh S, Sayan E, Thomas G, Packham G, Primrose J, Pichler M, Mirnezami A, Calin G, Bullock M.

Cancer Lett. 2018 May 1;421:94-102. doi: 10.1016/j.canlet.2018.02.022. Epub 2018 Feb 17.

PMID:
29458141
9.

Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.

Mora Vidal R, Regufe da Mota S, Hayden A, Markham H, Douglas J, Packham G, Crabb SJ.

Urology. 2018 Feb;112:225.e1-225.e7. doi: 10.1016/j.urology.2017.10.041. Epub 2017 Nov 15.

PMID:
29154981
10.

BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.

Papadakis ES, Reeves T, Robson NH, Maishman T, Packham G, Cutress RI.

Br J Cancer. 2017 Jun 6;116(12):1585-1594. doi: 10.1038/bjc.2017.130. Epub 2017 May 16. Review.

11.

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

Conforti F, Davies ER, Calderwood CJ, Thatcher TH, Jones MG, Smart DE, Mahajan S, Alzetani A, Havelock T, Maher TM, Molyneaux PL, Thorley AJ, Tetley TD, Warner JA, Packham G, Ganesan A, Skipp PJ, Marshall BJ, Richeldi L, Sime PJ, O'Reilly KMA, Davies DE.

Oncotarget. 2017 Jul 25;8(30):48737-48754. doi: 10.18632/oncotarget.17114.

12.

Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).

Borrello MT, Schinor B, Bartels K, Benelkebir H, Pereira S, Al-Jamal WT, Douglas L, Duriez PJ, Packham G, Haufe G, Ganesan A.

Bioorg Med Chem Lett. 2017 May 15;27(10):2099-2101. doi: 10.1016/j.bmcl.2017.03.081. Epub 2017 Mar 29.

PMID:
28390942
13.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Feb 9;3:17008. doi: 10.1038/nrdp.2017.8. No abstract available.

PMID:
28179635
14.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Jan 19;3:16096. doi: 10.1038/nrdp.2016.96. Review.

15.

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Drennan S, D'Avola A, Gao Y, Weigel C, Chrysostomou E, Steele AJ, Zenz T, Plass C, Johnson PW, Williams AP, Packham G, Stevenson FK, Oakes CC, Forconi F.

Leukemia. 2017 Aug;31(8):1686-1694. doi: 10.1038/leu.2016.356. Epub 2016 Nov 28.

PMID:
27890932
16.

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

Carter MJ, Cox KL, Blakemore SJ, Turaj AH, Oldham RJ, Dahal LN, Tannheimer S, Forconi F, Packham G, Cragg MS.

Leukemia. 2017 Jun;31(6):1423-1433. doi: 10.1038/leu.2016.333. Epub 2016 Nov 15.

17.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

18.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ.

Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

19.

Epigenetic modulators as therapeutic targets in prostate cancer.

Graça I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jerónimo C.

Clin Epigenetics. 2016 Sep 15;8:98. doi: 10.1186/s13148-016-0264-8. eCollection 2016. Review.

20.

PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.

Yeomans A, Lemm E, Wilmore S, Cavell BE, Valle-Argos B, Krysov S, Hidalgo MS, Leonard E, Willis AE, Forconi F, Stevenson FK, Steele AJ, Coldwell MJ, Packham G.

Oncotarget. 2016 Nov 15;7(46):74807-74819. doi: 10.18632/oncotarget.11655.

21.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

D'Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, Rose-Zerilli M, Strefford J, Plass C, Johnson PW, Steele AJ, Packham G, Stevenson FK, Oakes CC, Forconi F.

Blood. 2016 Aug 11;128(6):816-26. doi: 10.1182/blood-2016-03-707786. Epub 2016 Jun 14.

22.

A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.

Sbarrato T, Horvilleur E, Pöyry T, Hill K, Chaplin LC, Spriggs RV, Stoneley M, Wilson L, Jayne S, Vulliamy T, Beck D, Dokal I, Dyer MJ, Yeomans AM, Packham G, Bushell M, Wagner SD, Willis AE.

Cell Death Dis. 2016 Jun 2;7(6):e2249. doi: 10.1038/cddis.2016.148.

23.

Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. No abstract available.

PMID:
27230687
24.

IL-4 enhances expression and function of surface IgM in CLL cells.

Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, Smith LD, Linley A, Strefford JC, Davies A, Johnson PM, Savelyeva N, Cragg MS, Forconi F, Packham G, Stevenson FK, Steele AJ.

Blood. 2016 Jun 16;127(24):3015-25. doi: 10.1182/blood-2015-11-682906. Epub 2016 Mar 21.

25.

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.

Papadakis E, Robson N, Yeomans A, Bailey S, Laversin S, Beers S, Sayan AE, Ashton-Key M, Schwaiger S, Stuppner H, Troppmair J, Packham G, Cutress R.

Oncotarget. 2016 Apr 5;7(14):18851-64. doi: 10.18632/oncotarget.7944.

26.

Shooting the messenger (RNA) in B-cell lymphoma.

Yeomans A, Packham G.

Blood. 2016 Feb 18;127(7):794-6. doi: 10.1182/blood-2015-12-685156. No abstract available.

27.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21. Erratum in: Nat Genet. 2016 May 27;48(6):700.

28.

High throughput imaging cytometer with acoustic focussing.

Zmijan R, Jonnalagadda US, Carugo D, Kochi Y, Lemm E, Packham G, Hill M, Glynne-Jones P.

RSC Adv. 2015 Oct 31;5(101):83206-83216. doi: 10.1039/c5ra19497k. Epub 2015 Oct 1.

29.

Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, Leonard E, Ishfaq M, Wagner SD, Willis AE, Steele AJ, Stevenson FK, Forconi F, Coldwell MJ, Packham G.

Blood. 2016 Jan 28;127(4):449-57. doi: 10.1182/blood-2015-07-660969. Epub 2015 Oct 21.

30.

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, Duncombe A, Oscier D, Koide K, Forconi F, Packham G, Yoshida M, Cragg MS, Strefford JC, Steele AJ.

Leukemia. 2016 Feb;30(2):351-60. doi: 10.1038/leu.2015.286. Epub 2015 Oct 21.

PMID:
26488112
31.

T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Oldreive CE, Skowronska A, Davies NJ, Parry H, Agathanggelou A, Krysov S, Packham G, Rudzki Z, Cronin L, Vrzalikova K, Murray P, Odintsova E, Pratt G, Taylor AM, Moss P, Stankovic T.

Dis Model Mech. 2015 Nov;8(11):1401-12. doi: 10.1242/dmm.021147. Epub 2015 Aug 20.

32.

Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.

Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G, Stevenson FK.

Blood. 2015 Oct 15;126(16):1902-10. doi: 10.1182/blood-2015-04-640805. Epub 2015 Jul 20.

33.

BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma.

Carter MJ, Cox KL, Blakemore SJ, Bogdanov YD, Happo L, Scott CL, Strasser A, Packham GK, Cragg MS.

Cell Death Differ. 2016 Feb;23(2):303-12. doi: 10.1038/cdd.2015.97. Epub 2015 Jul 17.

34.

Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.

Zeidan B, Jackson TR, Larkin SE, Cutress RI, Coulton GR, Ashton-Key M, Murray N, Packham G, Gorgoulis V, Garbis SD, Townsend PA.

Oncotarget. 2015 Aug 28;6(25):21421-7.

35.

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.

Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, Johnson PW, Forconi F, Stevenson FK, Packham G, Cragg MS, Steele AJ.

Blood. 2015 Jun 25;125(26):4032-41. doi: 10.1182/blood-2014-11-610329. Epub 2015 May 8.

36.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose J, Packham G, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami A, Calin GA, Nicoloso MS.

Gut. 2016 Jun;65(6):977-989. doi: 10.1136/gutjnl-2015-309372. Epub 2015 Mar 24.

37.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

38.

Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.

Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H.

Blood. 2015 May 21;125(21):3287-96. doi: 10.1182/blood-2014-11-609404. Epub 2015 Mar 17.

39.

Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia.

Linley A, Valle-Argos B, Steele AJ, Stevenson FK, Forconi F, Packham G.

Haematologica. 2015 Jul;100(7):e265-8. doi: 10.3324/haematol.2014.120824. Epub 2015 Mar 6. No abstract available.

40.

Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, Potter KN, Kennedy B, Duncombe AS, Ashton-Key M, Forconi F, Stevenson FK, Packham G.

Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

41.

The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.

Stevenson FK, Forconi F, Packham G.

Semin Hematol. 2014 Jul;51(3):158-67. doi: 10.1053/j.seminhematol.2014.05.003. Epub 2014 May 15. Review.

PMID:
25048780
42.

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, Stevenson FK.

Haematologica. 2014 Jul;99(7):1138-48. doi: 10.3324/haematol.2013.098384. Review.

43.

Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.

Okosun J, Packham G, Fitzgibbon J.

Expert Opin Investig Drugs. 2014 Oct;23(10):1321-32. doi: 10.1517/13543784.2014.923402. Epub 2014 May 26. Review.

PMID:
24855903
44.

The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.

Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G, Crabb SJ.

Urol Oncol. 2014 Aug;32(6):806-14. doi: 10.1016/j.urolonc.2014.02.006. Epub 2014 May 16.

PMID:
24837013
45.

Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblasts.

Bullock MD, Mellone M, Pickard KM, Sayan AE, Mitter R, Primrose JN, Packham GK, Thomas G, Mirnezami AH.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51475.

46.

Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.

Duckworth A, Glenn M, Slupsky JR, Packham G, Kalakonda N.

Blood. 2014 May 22;123(21):3277-85. doi: 10.1182/blood-2013-11-539049. Epub 2014 Mar 17.

47.

A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.

Horvilleur E, Sbarrato T, Hill K, Spriggs RV, Screen M, Goodrem PJ, Sawicka K, Chaplin LC, Touriol C, Packham G, Potter KN, Dirnhofer S, Tzankov A, Dyer MJ, Bushell M, MacFarlane M, Willis AE.

Leukemia. 2014 May;28(5):1092-102. doi: 10.1038/leu.2013.295. Epub 2013 Oct 18.

48.

Isolation of a novel thioflavin S-derived compound that inhibits BAG-1-mediated protein interactions and targets BRAF inhibitor-resistant cell lines.

Enthammer M, Papadakis ES, Salomé Gachet M, Deutsch M, Schwaiger S, Koziel K, Ashraf MI, Khalid S, Wolber G, Packham G, Cutress RI, Stuppner H, Troppmair J.

Mol Cancer Ther. 2013 Nov;12(11):2400-14. doi: 10.1158/1535-7163.MCT-13-0142. Epub 2013 Sep 18.

49.

Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.

Coelho V, Krysov S, Steele A, Sanchez Hidalgo M, Johnson PW, Chana PS, Packham G, Stevenson FK, Forconi F.

Blood. 2013 Oct 10;122(15):2664-72. doi: 10.1182/blood-2013-02-485425. Epub 2013 Aug 16.

50.

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH.

Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.

Supplemental Content

Loading ...
Support Center